AMGX.F Stock Overview
A biopharmaceutical company, engages in the research and development of gene-based medical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AnGes, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.41 |
| 52 Week High | JP¥0.56 |
| 52 Week Low | JP¥0.34 |
| Beta | 0.68 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -88.01% |
| 5 Year Change | n/a |
| Change since IPO | -93.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMGX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.7% | 0.3% |
| 1Y | n/a | 15.2% | 31.1% |
Return vs Industry: Insufficient data to determine how AMGX.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AMGX.F performed against the US Market.
Price Volatility
| AMGX.F volatility | |
|---|---|
| AMGX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMGX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AMGX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 145 | Ei Yamada | www.anges.co.jp |
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University.
AnGes, Inc. Fundamentals Summary
| AMGX.F fundamental statistics | |
|---|---|
| Market cap | US$84.28m |
| Earnings (TTM) | -US$63.48m |
| Revenue (TTM) | US$3.38m |
25.9x
P/S Ratio-1.4x
P/E RatioIs AMGX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMGX.F income statement (TTM) | |
|---|---|
| Revenue | JP¥521.00m |
| Cost of Revenue | JP¥329.00m |
| Gross Profit | JP¥192.00m |
| Other Expenses | JP¥9.99b |
| Earnings | -JP¥9.79b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -39.92 |
| Gross Margin | 36.85% |
| Net Profit Margin | -1,880.04% |
| Debt/Equity Ratio | 5.9% |
How did AMGX.F perform over the long term?
See historical performance and comparison